Status:
COMPLETED
Combined F-18 NaF and F-18 FDG PET/CT for Evaluation of Malignancy
Lead Sponsor:
Stanford University
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Brief Summary
Fluorine-18 Fluorodeoxyglucose (F-18 FDG) PET/CT is established as a powerful imaging tool for cancer detection and monitoring response to therapy. Sodium Fluorine-18 (F-18) was used in the 1970s for ...
Eligibility Criteria
Inclusion
- Patients older than 18-year-old, diagnosed with cancer
- Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them
Exclusion
- Patients who cannot complete a PET/CT scan
- Pregnant women
- Healthy volunteers
- Patients participating in other research studies
- The subjects will not be paid to participate in this protocol. No costs will be charged to the subjects.
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
214 Patients enrolled
Trial Details
Trial ID
NCT00725387
Start Date
August 1 2007
End Date
June 1 2019
Last Update
September 18 2019
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305
2
Aalborg Hospital
Aalborg, Denmark
3
Apollo Hospital
Chennai, India
4
Coimbra University Hospital
Coimbra, Portugal